The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: bevacizumab     Quarter: 2016Q3

Total Drug/Injury Combinations: 786     Number of Pages: 40

DRUGNAME PT EventCount
Bevacizumab Malnutrition 2 view events
Bevacizumab Mental status changes 2 view events
BEVACIZUMAB Metabolic disorder 2 view events
Bevacizumab Metastases to central nervous system 2 view events
Bevacizumab Metastases to lung 2 view events
Bevacizumab Monoparesis 2 view events
Bevacizumab Multimorbidity 2 view events
Bevacizumab Muscle haemorrhage 2 view events
Bevacizumab Muscle spasms 2 view events
BEVACIZUMAB Muscle tightness 2 view events
BEVACIZUMAB Musculoskeletal discomfort 2 view events
BEVACIZUMAB Musculoskeletal stiffness 2 view events
Bevacizumab Myelodysplastic syndrome 2 view events
Bevacizumab Myositis 2 view events
BEVACIZUMAB Nasal septum perforation 2 view events
BEVACIZUMAB Necrotising fasciitis 2 view events
Bevacizumab Neoplasm malignant 2 view events
Bevacizumab Nervous system disorder 2 view events
BEVACIZUMAB Neuroectodermal neoplasm 2 view events
Bevacizumab Oesophageal haemorrhage 2 view events

Total Drug/Injury Combinations: 786     Number of Pages: 40

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)